RxDoctor Payments Data

Cong Zhi Zhao, MD

Neurology · Fresno, CANPI 1629248661

Payments from drug & device makers

$212,505in general payments, 2019–2025

Across 538 payments — averaging $394.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$98K
  • Boston Scientific$87K
  • Acorda Therapeutics, Inc$11K
  • Kyowa Kirin, Inc.$7K
  • Medtronic$2K
  • Abbott$2K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$2,8602%
  • Speaking & faculty fees$108,03985%
  • Travel & lodging$4,8974%
  • Food & beverage$11,5049%
  • Education$2170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$212,505 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$71,378
Medicare patients
259
Services billed
2,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa131$186,581
AustedoDeutetrabenazine31$157,589
GocovriAmantadine Hcl18$85,351
NuplazidPimavanserin Tartrate17$78,531
NeuproRotigotine49$76,832
DuopaCarbidopa/Levodopa11$66,102
CopaxoneGlatiramer Acetate11$62,356
Carbidopa-Levodopa ErCarbidopa/Levodopa284$28,809
Carbidopa-LevodopaCarbidopa/Levodopa731$28,255
NuedextaDextromethorphan Hbr/Quinidine12$18,678
Tetrabenazine34$15,032
Rasagiline Mesylate59$14,421
Entacapone44$13,950
Midodrine Hcl24$7,832
AmantadineAmantadine Hcl86$7,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$98,451$219,94542 claims
Amneal Pharmaceuticals LLCRytary$209$186,581131 claims
Acadia Pharmaceuticals IncNuplazid$285$78,53117 claims
UCB, Inc.Neupro$24$76,83249 claims
AbbVieDuopa$1,016$66,10211 claims
Upsher-smith Laboratories LLCTopiramate$49$90044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →